Company intelligence / Profile preview

Oroxcell

Romainville, Île-de-France, France

Ownership: Private
Employees: ~30
Development stage: Other

Overview

Oroxcell is a specialized Contract Research Organization (CRO) based in France, providing a comprehensive range of services in ADME, bioanalysis, and toxicology. The company serves the pharmaceutical, cosmetic, and chemical industries, offering expertise in pharmacokinetics and safety assessment. Oroxcell is notably recognized for its innovative in vitro models, including 3D reconstructed human tissues for skin and mucosal testing. Following its acquisition by Eurofins Scientific in 2021, Oroxcell operates as part of Eurofins' extensive global laboratory network, continuing to support drug development and product safety evaluations.

Modalities: Small moleculePeptidesBiologic
Industry: Contract Research Organization

Beyond the preview

Go deeper on Oroxcell.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oroxcell.

Explore the full profile